Key takeaways
View morePfizer appears significantly undervalued based on multiple metrics, including EV/EBITDA of 7.85x versus industry average of 67.41x, while maintaining strong fundamentals with above-industry profitability metrics and robust growth prospects from the Seagen acquisition and pipeline developments. While risks exist, including IRA impacts and patent expirations, these appear more than priced into current valuations, especially given the company's strong market position and operational efficiency initiatives.
- Pfizer's ROA, ROE, and Return on Average Total Capital significantly outperform industry averages, indicating superior profitability.
- The acquisition of Seagen is a key growth driver, expected to contribute substantially to oncology revenue.
- The IRA Medicare Part D redesign is projected to create a $1 billion headwind, impacting revenue from higher-priced drugs.
- Pfizer's Enterprise Value to EBITDA and Enterprise Value to Sales ratios are significantly lower than industry averages, suggesting potential undervaluation.
- Pfizer's stock has underperformed peers BMY and SAN over the past year, but has shown recent outperformance in shorter time frames.
- The company's debt-to-equity ratio of 68.75% is lower than the industry average of 115.91%, indicating lower leverage.
- Pfizer's 2025 guidance projects revenue in the $61 billion to $64 billion range and adjusted diluted EPS of $2.80 to $3.00, representing operational EPS growth of 10% to 18%.
- The company is targeting $1.5 billion in manufacturing cost reductions by the end of 2027, enhancing future profitability.
- Pfizer's maximum drawdown of -58.96% on 04/10/2025 indicates a higher risk profile compared to peers and the XLV benchmark.
Evaluation summary
-
Company Overview:
- Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide. Key products include Comirnaty (COVID-19 vaccine), Paxlovid (COVID-19 oral treatment), Eliquis, Vyndaqel/Vyndamax, Ibrance, Xeljanz, and various oncology, hospital, and biosimilar products. The company's major customers include wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies.
- Pfizer's performance is benchmarked against the Health Care Select Sector SPDR Fund (XLV). Peer companies for comparison include Bristol Myers Squibb Co. (BMY) and Sanofi (SAN).
-
Financial Performance:
- Pfizer's sales revenue has fluctuated quarterly, with $13.715 billion reported for the quarter ending March 31, 2025, compared to $17.763 billion for the quarter ending December 31, 2024. Net income for the same periods was $2.967 billion and $403 million, respectively, showing significant volatility.
- Gross profit margin was 71.65% for the quarter ending March 31, 2025, and 73.01% for the quarter ending December 31, 2024. Net profit margin was 21.63% and 2.27% for the same periods, respectively. These figures indicate fluctuating profitability.
- Pfizer's Return on Average Assets (ROA) was 3.67% for the quarter ending March 31, 2025, compared to an industry average of -64.33%. Return on Average Total Equity (ROE) was 8.62% compared to an industry average of -484.78%. Return on Average Total Capital was 10.92% compared to an industry average of -135.82%. These metrics show that Pfizer significantly outperforms the industry average in profitability.
- The earnings call highlighted that the IRA Medicare Part D redesign is expected to be a $1 billion headwind, impacting higher-priced medicines like Vyndaqel and Ibrance.
-
Operational Efficiency:
- Total current assets were $45.861 billion as of March 31, 2025, compared to $50.358 billion as of December 31, 2024. Total current liabilities were $36.452 billion and $42.995 billion for the same periods, respectively.
- Working capital was $9.409 billion as of March 31, 2025, and $7.363 billion as of December 31, 2024, indicating a fluctuating but positive working capital position.
- Net operating cash flow was $2.335 billion for the quarter ending March 31, 2025, and $6.721 billion for the quarter ending December 31, 2024. Total capital expenditure was $564 million and $917 million for the same periods, respectively.
- Free cash flow to equity was $1.771 billion for the quarter ending March 31, 2025, and $5.804 billion for the quarter ending December 31, 2024. Free cash flow margin was 0.13 and 0.33 for the same periods, respectively.
- Capital expenditure was $564 million for the quarter ending March 31, 2025, while depreciation, depletion, and amortization were $1.618 billion.
- Cash dividends paid were $2.437 billion for the quarter ending March 31, 2025, and $2.380 billion for the quarter ending December 31, 2024.
- The current ratio was 1.26 as of March 31, 2025, compared to an industry average of 6.80. The quick ratio was 0.96 compared to an industry average of 6.64.
- The total debt to total equity ratio was 68.75% as of March 31, 2025, compared to an industry average of 115.91%. Debt/EBITDA was 2.58 compared to an industry average of 6.30.
-
Growth Opportunities:
- The Seagen acquisition is expected to drive oncology growth, with five Phase 3 studies initiated, including next-generation CDK4 inhibitors and ADCs.
- Pfizer is making progress in its pipeline across various therapeutic areas, including oncology, cancer cachexia, obesity, next-generation oral COVID treatment, and vaccines for flu/COVID and C. difficile.
- The company is focused on driving operational efficiency and reducing manufacturing costs by $1.5 billion by the end of 2027.
- The appointment of a new Chief Scientific Officer and President of R&D signals a commitment to advancing the pipeline.
- Management indicated that business development is expected to accelerate in 2026 and beyond.
-
Recent Developments and Market Sentiment:
- The acquisition of Seagen in December 2023 for $44.2 billion is a significant development, expected to contribute substantially to oncology growth.
- Pfizer launched multi-year cost realignment and manufacturing optimization programs to improve margins.
- The company voluntarily withdrew Oxbryta (voxelotor) for sickle cell disease due to safety concerns.
- The market sentiment appears cautiously optimistic, with analysts focusing on the successful integration of Seagen, pipeline advancements, and cost-reduction programs. However, concerns remain regarding the impact of the IRA and competition in various markets.
-
Risks and Threats:
- Pfizer faces risks related to R&D activities, regulatory approvals, product safety/efficacy, and commercial performance of new and existing products.
- Intellectual property challenges and generic/biosimilar competition pose ongoing threats.
- Pricing and reimbursement pressures from governments and payors are significant concerns.
- Supply chain disruptions, manufacturing issues, and product recalls could negatively impact performance.
- Legal and regulatory compliance, including government investigations and litigation, present ongoing risks.
- The SEC filings mention that Pfizer is involved in various patent litigation cases and faces product liability litigation.
-
Valuation Analysis:
- The Enterprise Value to EBITDA was 7.85 as of March 31, 2025, compared to an industry average of 67.41. The Enterprise Value to Sales was 3.03 compared to an industry average of 8757.21.
- These metrics suggest that Pfizer may be undervalued compared to its industry peers.
- Potential catalysts include the successful integration of Seagen, positive clinical trial results, and new product launches.
-
Price Performance:
- Pfizer's stock price has fluctuated between $22.28 and $25.32 from May 5, 2025, to July 2, 2025.
- Over the past year, PFE has underperformed both BMY and SAN, with returns of -2.48% compared to 24.74% for BMY and 5.89% for SAN. However, in shorter time frames such as the last month and three months, PFE has significantly outperformed both peer companies.
- Compared to the Health Care Select Sector SPDR Fund (XLV), PFE has shown mixed performance. While PFE has shown short-term outperformance, its long-term underperformance, higher volatility, larger drawdowns, and lower Sharpe Ratios suggest a higher risk profile and less efficient risk-adjusted returns compared to XLV.
-
Future Outlook:
- Pfizer reaffirmed its full-year 2024 revenue guidance of $61 billion to $64 billion and adjusted diluted EPS of $2.75 to $2.95.
- 2025 guidance projects revenue in the $61 billion to $64 billion range and adjusted diluted EPS of $2.80 to $3.00, representing operational EPS growth of 10% to 18% and margin expansion of over 250 basis points.
- Key risks include the impact of the IRA, competition in various markets, and potential fluctuations in Paxlovid revenue based on COVID-19 infection rates.
- Opportunities lie in the continued growth of its diversified portfolio, particularly in oncology, and the successful execution of its cost-reduction programs.
-
Summary:
- Pfizer is a global biopharmaceutical company with a diversified portfolio and a strong focus on oncology. The company's financial performance has been mixed, with fluctuating revenue and profitability. However, Pfizer significantly outperforms the industry average in profitability metrics such as ROA, ROE, and Return on Average Total Capital.
- Strengths include a strong oncology pipeline, successful integration of Seagen, and a commitment to cost reduction. Weaknesses include reliance on a few key products and exposure to pricing pressures. Opportunities lie in continued growth in oncology and successful execution of cost-reduction programs. Threats include competition, regulatory challenges, and intellectual property risks.
- Pfizer's financial health is strong, with ample liquidity and a decreasing debt-to-equity ratio. However, the company faces challenges related to the IRA and competition.
- Critical factors for future performance include the successful integration of Seagen, pipeline advancements, and cost management.
- Areas requiring further monitoring include the impact of the IRA, competition in various markets, and potential fluctuations in Paxlovid revenue.
- Overall, Pfizer presents a mixed investment profile. The company has strong growth potential in oncology and a commitment to cost reduction. However, it faces significant risks related to competition, regulation, and intellectual property. The valuation appears reasonable compared to industry peers.
Price history
Fundamentals
Insights
- Pfizer's revenue growth has decelerated, but profitability has improved due to effective cost management.
- The company's liquidity position is adequate but lower than the industry average, requiring careful management.
- Pfizer's long-term solvency is strong, with a decreasing debt-to-equity ratio and lower leverage compared to peers.
- The company's operational efficiency is improving, with superior production efficiency compared to industry peers.
- Pfizer faces risks related to market conditions, competition, and the success of new product launches, but is expected to continue growing revenue and improving profitability.
Analysis
- Revenue
- Sales revenue has shown an increasing trend, indicating growth in the company's top line.
- However, the growth rate has decelerated compared to previous years, as indicated by the negative difference between the 3-year and 5-year CAGR.
- The company's ability to sustain revenue growth will depend on factors such as market conditions, competition, and the success of new product launches.
- Profitability
- Profitability margins have improved, as indicated by the increasing trends in gross profit margin, operating margin, and net profit margin.
- Effective cost management has played a significant role in enhancing the company's profitability.
- The company's profitability is significantly greater than the industry average, indicating superior performance compared to peers.
- Liquidity
- The company's liquidity position is adequate, as indicated by the current ratio, but lower than the industry average.
- Liquidity has been improving, as indicated by the increasing trends in the current ratio and quick ratio.
- Careful liquidity management is necessary to ensure that the company can meet its short-term obligations.
- Solvency
- The company's long-term solvency is strong, with a decreasing debt-to-equity ratio.
- The company's leverage is lower than the industry average, providing more financial flexibility.
- The company is focused on deleveraging, which will further improve its financial stability.
- Operational Efficiency
- The company's operational efficiency is improving, as indicated by the decreasing trends in enterprise value to sales and enterprise value to EBITDA.
- The company's gross profit margin is significantly greater than the industry average, indicating superior production efficiency compared to peers.
- The company's ability to sustain these trends will depend on factors such as cost management, product mix, and operational improvements.
- Cash Flow Analysis - Net income and funds from operations show increasing trends, indicating improved cash generation from core business activities. - Changes in working capital have been volatile, reflecting the impact of changes in inventory, accounts receivable, and accounts payable. - Cash dividends paid have increased steadily, reflecting the company's commitment to returning value to shareholders.
- Risk Factors
- The company faces risks related to market conditions, competition, and the success of new product launches.
- The company's reliance on a few key products could make it vulnerable to patent expirations or generic competition.
- The company's acquisition strategy could lead to integration challenges or overpayment for acquired assets.
- Future Outlook
- The company is expected to continue growing its revenue and improving its profitability.
- The company is expected to continue deleveraging and returning value to shareholders through dividends and share repurchases.
- The company's future performance will depend on its ability to successfully execute its strategic initiatives and manage its risks.
- Profitability
Financial statements
Public filings
- Pfizer is facing increasing pricing and competitive pressures, but has diversified its portfolio beyond COVID-19 products through the acquisition of Seagen and other pipeline advancements
- The company is proactively managing costs through restructuring and optimization initiatives to improve margins, while continuing to invest in R&D to drive future growth
- Intellectual property protection, regulatory approvals, and managing supply chain and manufacturing risks are critical to Pfizer's business performance
- Significant legal and government investigations pose ongoing risks that could result in fines, penalties, or other adverse outcomes
- Pfizer's financial position remains strong, with ample liquidity to fund operations and strategic initiatives, though the timing of cash flows may be uneven due to the seasonality of certain products
Core Business and Operations:
- Pfizer Inc. is a research-based, global biopharmaceutical company that discovers, develops, manufactures, markets, and distributes biopharmaceutical products worldwide
- Key products include Comirnaty (COVID-19 vaccine), Paxlovid (COVID-19 oral treatment), Eliquis, Vyndaqel/Vyndamax, Ibrance, Xeljanz, and various oncology, hospital, and biosimilar products
- Major customers include wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies
- Competes with other pharmaceutical and biotechnology companies, generic drug manufacturers, and biosimilar product developers
Industry and Market Trends:
- Facing pricing pressures and cost control efforts from governments and payors globally, including implementation of drug pricing provisions in the Inflation Reduction Act (IRA)
- Intellectual property rights and patent expirations can significantly impact revenues for key products
- Regulatory environment and ability to obtain approvals for new products/indications is critical
- COVID-19 pandemic has significantly impacted demand and sales of Pfizer's COVID-19 products
Recent Events:
- Acquired Seagen, a global biotechnology company, in December 2023 for $44.2 billion
- Launched multi-year cost realignment and manufacturing optimization programs to improve margins
- Sold portions of its investment in Haleon, reducing ownership from 32% to approximately 15%
- Voluntarily withdrew Oxbryta (voxelotor) for sickle cell disease due to safety concerns
Risk Factors:
- Risks related to R&D activities, regulatory approvals, product safety/efficacy, and commercial performance of new and existing products
- Intellectual property challenges and generic/biosimilar competition
- Pricing and reimbursement pressures from governments and payors
- Supply chain disruptions, manufacturing issues, and product recalls
- Macroeconomic conditions, geopolitical events, and public health crises (e.g. COVID-19)
- Legal and regulatory compliance, including government investigations and litigation
Legal Matters:
- Involved in various patent litigation cases, including challenges to patents covering key products
- Facing product liability and other litigation related to current and former products
- Subject to government investigations related to sales practices, manufacturing operations, and other matters
Management's Discussion and Analysis:
- Total revenues increased 2% in the first nine months of 2024, driven by growth in Paxlovid, Seagen products, and the Vyndaqel family, offset by declines in Comirnaty
- Cost of sales decreased 12% in the first nine months of 2024, reflecting lower Comirnaty sales and non-recurrence of prior year inventory write-offs
- Operating expenses increased due to higher amortization, restructuring costs, and charges related to the discontinuation of the DMD program
- Effective tax rate was 4.9% in the first nine months of 2024, down from (6.2)% in the prior year period
- Maintained strong liquidity position with access to credit facilities and ability to generate robust operating cash flows
Earnings calls
Earnings Report 2025Q1 (2024-12-17)
Key takeaways
-
Strong 2024 Performance and Stable 2025 Outlook: Pfizer delivered strong results in 2024, exceeding expectations in several areas. The 2025 guidance reflects a transition to a more stable revenue environment, with a focus on operational efficiency driving significant EPS growth.
-
IRA Impact and Pricing Pressures: The IRA Medicare Part D redesign presents a significant headwind, impacting higher-priced drugs. Management acknowledged pricing pressures in several markets, highlighting the need for strategic cost management and operational efficiency.
-
Oncology Growth and Seagen Integration: The Seagen acquisition is proving transformative, contributing significantly to oncology growth. The pipeline of ADC and other oncology assets offers substantial long-term growth potential.
-
Pipeline Advancement and R&D Focus: Pfizer's robust pipeline, particularly in oncology, is a key driver of future growth. The appointment of a new R&D leader signals a renewed focus on innovation and strategic prioritization of R&D investments.
-
Strategic Capital Allocation: Pfizer's strategic capital allocation, balancing de-leveraging, dividend growth, and future business development, is crucial for long-term shareholder value creation.
Focus of management’s prepared remarks
-
Seagen Integration and Oncology Leadership: The integration of Seagen has been highly successful, resulting in a strong oncology team and contributing to year-to-date growth. Five Phase 3 studies have been initiated, including next-generation CDK4 inhibitors and ADCs, with potential for mega-blockbuster drugs. Long-term follow-up data for Lorbrena has led to rapid global adoption. Eight first-in-patient studies have been initiated, including studies of two new ADCs and a panKRAS inhibitor.
-
Pipeline Advancement: Significant progress has been made in the pipeline across various therapeutic areas, including oncology, cancer cachexia, obesity, next-generation oral COVID treatment, and vaccines for flu/COVID and C. difficile. A fifth-generation pneumococcal vaccine candidate is also in development.
-
Commercial Success and Cost Realignment: Strong commercial results have been achieved in both the US and internationally. The new US commercial model is yielding benefits, and the international organization is capitalizing on global reach. The company achieved its $4 billion cost savings goal and expects an additional $500 million in 2025, along with $1.5 billion in manufacturing cost reductions by the end of 2027.
-
Financial Discipline and Capital Allocation: Pfizer demonstrated good progress with financial discipline, maintaining a commitment to its dividend and strategically allocating capital. The Seagen and BioNTech deals are highlighted as transformational.
-
New R&D Leadership: Dr. Chris Boshoff's appointment as Chief Scientific Officer and President of R&D is expected to bring discipline and strategic focus to R&D investments. He will partner with the Chief Strategy and Innovation Officer to prioritize impactful opportunities.
Focus of the analyst Q&A
-
Gross Margins and Capital Allocation: Analysts inquired about the potential for further gross margin improvement beyond the mid-70s target in 2025, considering the manufacturing optimization program and other opportunities. Questions also focused on capital allocation priorities in 2025, specifically whether business development or capital return might accelerate beyond de-leveraging.
-
Capital Allocation Priorities and Potential Spin-off: Analysts sought clarification on the relative priorities of dividend growth and de-leveraging in 2025. There were also questions regarding market chatter about a potential spin-off of the hospital business and the potential use of proceeds.
-
Revenue Stability and Long-Term Growth Aspirations: Analysts asked whether "revenue stability" implied flat revenue through the end of the decade or consistent growth, and whether Pfizer might reinstate its previous 6% longer-term revenue aspiration.
-
Drug Pricing in the US and Internationally: Analysts sought commentary on drug pricing, particularly in the US with IRA implementation and internationally, including discussions around "most favored nation" pricing and potential price increases outside the US.
-
Impact of Part D on Specific Drugs and Operational Expenses: Analysts requested a more detailed breakdown of the Medicare Part D impact per drug, including identification of potential winners and losers. They also inquired about the operational expense budget's ability to accommodate a large Phase 3 program in obesity and potential changes based on upcoming data.
-
Comirnaty Revenue and Pipeline Events: Analysts asked about the potential impact of anti-vaccine sentiment on Comirnaty revenue, even without policy changes. They also sought information on key upcoming pipeline events beyond the danuglipron readout in Q1 2025.
-
Seagen Acquisition Growth Profile: Analysts inquired about the expected growth contribution of Seagen assets to Pfizer's overall revenue growth, identifying key growth drivers beyond Padcev.
Summary
-
Financial Performance: Pfizer reaffirmed its full-year 2024 revenue guidance of $61 billion to $64 billion and adjusted diluted EPS of $2.75 to $2.95. Excluding one-time Paxlovid revenues and non-recurring items, the baseline midpoint for 2024 is $61.3 billion in revenue and $2.55 in adjusted diluted EPS. 2024 year-to-date performance showed strong results across a diversified portfolio, driven by successful Seagen integration and a new commercial model. The company achieved its $4 billion cost savings goal. 2025 guidance projects revenue in the $61 billion to $64 billion range and adjusted diluted EPS of $2.80 to $3.00, representing operational EPS growth of 10% to 18% and margin expansion of over 250 basis points.
-
Revenue Drivers: Key revenue drivers in 2025 include stable revenue from Comirnaty and Paxlovid (though Paxlovid will see a shift in revenue recognition due to changes in patient assistance programs), continued growth from Eliquis and Nurtec, and significant contributions from oncology, particularly Lorbrena and Padcev. However, the IRA Medicare Part D redesign is expected to be a $1 billion headwind, impacting higher-priced medicines like Vyndaqel and Ibrance. Prevnar revenue is expected to moderately decline due to competition in the adult indication, while Abrysvo's growth will be tempered by competition and a narrowing US market. The Seagen acquisition's impact on oncology growth will be mathematically dampened in 2025 due to the overlapping effect of the acquisition.
-
Profit Margins and Cost Management: Pfizer aims for mid-70s adjusted gross margin in 2025, incorporating the initial savings from Phase 1 of its manufacturing optimization program. The company expects an additional $500 million in cost savings in 2025, building on the $4 billion achieved in 2024. Management indicated that upper 70s gross margins are a realistic longer-term target, achievable through the continued rollout of the manufacturing optimization program. Adjusted SI&A and R&D expenses are projected to be in the $24 billion to $26 billion range in 2025.
-
Guidance and Outlook: Pfizer's 2025 guidance reflects a more stable revenue outlook compared to previous years, with the COVID-related variability largely in the past. The company anticipates modest revenue growth (flat to up 5%) but significant EPS growth (10% to 18%) due to operational efficiency. Key risks include the impact of the IRA, competition in various markets, and potential fluctuations in Paxlovid revenue based on COVID-19 infection rates. Opportunities lie in the continued growth of its diversified portfolio, particularly in oncology, and the successful execution of its cost-reduction programs.
-
Strategic Initiatives: Key strategic initiatives include the successful integration of Seagen, the formation of Pfizer Oncology, and the implementation of a new commercial model. The company is focused on driving operational efficiency, reducing manufacturing costs by $1.5 billion by the end of 2027, and strategically allocating capital to enhance shareholder value. The appointment of a new Chief Scientific Officer and President of R&D signals a commitment to advancing the pipeline. De-leveraging remains a priority for 2025, alongside maintaining and growing the dividend. Business development is expected to accelerate in 2026 and beyond.
-
Management Commentary: Management expressed confidence in the company's strong position and its ability to deliver on financial commitments. They highlighted the successful integration of Seagen, strong pipeline progress, and the positive impact of the new commercial model. The overall tone was optimistic, emphasizing revenue stability, margin expansion, and the potential for significant long-term growth. Management also discussed the importance of strategic capital allocation and their commitment to shareholder value.
-
Industry and Market Conditions: Pfizer acknowledges the impact of the IRA Medicare Part D redesign and increased competition in several markets. Management noted the stability in COVID-19 product revenue, with expectations for continued utilization based on historical infection patterns. The company anticipates continued growth in oncology, driven by the Seagen acquisition and its own pipeline advancements. The shift away from chemotherapy towards targeted therapies, such as ADCs, presents a significant opportunity for growth.
Comparative analysis
Benchmarks (as of 2025-07-02)
- Performance Comparison:
- Pfizer Inc. (PFE) has shown mixed performance compared to the Health Care Select Sector SPDR Fund (XLV). Over the short term (1 Week, 1 Month, 3 Months, 6 Months, and 1 Year), PFE has outperformed XLV. However, over the longer term (2 Years and 3 Years), PFE has significantly underperformed XLV. For example, over the past three years, PFE's return was -42.73% compared to XLV's 10.26%.
- Risk and Return Analysis:
- The annualized returns indicate that PFE has underperformed XLV over the 2-year and 3-year periods. Specifically, the 3-year annualized return for PFE is -16.96%, while for XLV it is 3.31%.
- Pfizer Inc. (PFE) generally exhibited higher annualized volatility than the Health Care Select Sector SPDR Fund (XLV) throughout the period. For example, in Q3 2022, PFE's volatility ranged from 18.37% to 31.95%, while XLV's ranged from 14.43% to 23.63%.
- Pfizer Inc. (PFE) experienced significantly larger drawdowns than the Health Care Select Sector SPDR Fund (XLV). The maximum drawdown for PFE was -58.96% on 2025-04-10, while the maximum drawdown for XLV was -17.11% on 2025-05-14. This indicates a higher risk profile for PFE.
- Risk-Adjusted Performance:
- The Health Care Select Sector SPDR Fund (XLV) generally exhibited higher Sharpe Ratios than Pfizer Inc. (PFE) throughout the observed period, indicating better risk-adjusted returns.
- The beta values for both Pfizer Inc. (PFE) and the Health Care Select Sector SPDR Fund (XLV) were consistently below 1 throughout the entire period, indicating lower sensitivity to market movements compared to the broader market. However, XLV consistently had higher beta values than PFE, indicating that XLV's price is more sensitive to market movements than PFE's.
- Overall Assessment:
- Pfizer Inc. (PFE) has demonstrated mixed performance compared to the Health Care Select Sector SPDR Fund (XLV). While PFE has shown short-term outperformance, its long-term underperformance, higher volatility, larger drawdowns, and lower Sharpe Ratios suggest a higher risk profile and less efficient risk-adjusted returns compared to XLV. The consistently lower beta of PFE indicates it is less sensitive to overall market movements than XLV.
- The significant trends include the higher volatility and drawdown risks associated with PFE, as well as its recent short-term outperformance. These factors should be carefully considered when making investment decisions.
Peers Price History(as of 2025-07-02)
- Performance Comparison:
- Pfizer Inc. (PFE) has shown mixed performance compared to Bristol Myers Squibb Co. (BMY) and Sanofi (SAN). Over the past year, PFE has underperformed both BMY and SAN, with returns of -2.48% compared to 24.74% for BMY and 5.89% for SAN. However, in shorter time frames such as the last month and three months, PFE has significantly outperformed both peer companies. For example, over the last three months, PFE returned 6.23% compared to -16.73% for BMY and -6.33% for SAN.
- Risk and Return Analysis:
- The annualized returns show that PFE has underperformed both BMY and SAN over the 1-year and 2-year periods. The 1-year annualized return for PFE is -2.48%, while BMY is 24.74% and SAN is 5.89%.
- In terms of annualized volatility, Sanofi (SAN) generally exhibited higher volatility compared to Pfizer Inc. (PFE) and Bristol Myers Squibb Co. (BMY), especially in late 2023. For example, in Q4 2023, SAN's volatility ranged from 12.85% to 59.03%, while PFE's ranged from 17.52% to 34.41% and BMY's ranged from 9.86% to 31.4%.
- Pfizer Inc. (PFE) experienced the largest maximum drawdown of -58.96% on 04/10/2025, while Bristol Myers Squibb Co. (BMY) had a maximum drawdown of -47.67% on 07/03/2024, and Sanofi (SAN) had a maximum drawdown of -32.84% on 09/27/2022. This indicates that PFE has a higher risk profile in terms of potential peak-to-trough declines.
- Risk-Adjusted Performance:
- Bristol Myers Squibb Co. (BMY) generally had higher Sharpe Ratios compared to Pfizer Inc. (PFE), indicating better risk-adjusted returns. Sanofi (SAN) also showed competitive Sharpe Ratios, especially in certain periods. For example, in Q4 2024, BMY's Sharpe Ratio ranged from 0.06 to 0.99, while PFE's ranged from -0.25 to 0.27.
- The beta values for all three companies were consistently below 1 throughout the period, indicating lower volatility compared to the market. In Q3 2025, beta values were stable, with PFE at 0.41, BMY at 0.24, and SAN at -0.09.
- Overall Assessment:
- Pfizer Inc. (PFE) has shown mixed performance compared to its peer companies. While it has outperformed in shorter time frames, it has underperformed over the longer term. PFE also exhibits higher volatility and larger drawdowns compared to BMY and SAN, indicating a higher risk profile. BMY generally offers better risk-adjusted returns, as indicated by its higher Sharpe Ratios.
- A significant trend is the higher volatility experienced by Sanofi (SAN) in late 2023, which was not mirrored by PFE or BMY. Additionally, PFE's large maximum drawdown on 04/10/2025 is an anomaly that could inform investment decisions, suggesting a need for caution regarding potential downside risk.
Peers Fundamentals(as of 2025-03-31)
-
Market Position and Size:
- Pfizer (PFE) leads its peer group in market capitalization, with a valuation of $129797 million, surpassing Bristol Myers Squibb (BMY) at $95140 million and Sanofi (SAN) at $111821 million.
- This market leadership is supported by Pfizer's higher revenue of $62463 million and EBITDA of $24091 million, indicating a larger scale of operations and greater market influence.
- Pfizer's dominant market position is a key strength, reflecting its extensive product portfolio and global reach.
-
Profitability and Efficiency:
- Pfizer demonstrates strong profitability with a gross profit margin of 66.93%, exceeding both BMY (59.16%) and SAN (63.49%).
- Its EBITDA margin of 38.57% is competitive within the peer group, although slightly lower than BMY's 39.78%.
- However, Pfizer's return on equity (8.62%) lags behind BMY (31.99%), suggesting potential inefficiencies in utilizing equity to generate profits.
-
Financial Health and Stability:
- Pfizer maintains a conservative capital structure with a debt-to-equity ratio of 68.75, significantly lower than BMY's 294.66, indicating less reliance on debt financing.
- Its current ratio of 1.26 and quick ratio of 0.96 are slightly below industry averages, raising potential liquidity concerns.
- Overall, Pfizer's financial health is stable, supported by its strong cash flow and conservative debt management.
-
Valuation and Market Perception:
- Pfizer's valuation metrics, including a P/E ratio of 16.55 and a price-to-sales ratio of 2.09, are generally lower than its peers, suggesting it may be undervalued by the market.
- Its enterprise value-to-EBITDA ratio of 7.85 is also lower than BMY's 8.57, further indicating a potentially attractive valuation.
- The market's perception of Pfizer may be influenced by concerns about future growth prospects or patent expirations.
-
Cash Flow and Capital Management:
- Pfizer generates strong cash flow from operations, with a net operating cash flow of $13988 million.
- Its free cash flow of $11219 million is robust, although slightly lower than BMY's $13086 million.
- Pfizer's capital expenditure of $2769 million reflects ongoing investments in research and development and infrastructure.
-
Growth and Future Prospect:
- Pfizer's revenue growth has been inconsistent, with a 5-year CAGR of 4.28% and a 3-year CAGR of -12.29%, indicating a recent slowdown.
- However, its EBITDA growth has been strong, with a recent year-over-year increase of 189.62%, suggesting improved operational efficiency.
- Future growth prospects may depend on the success of its pipeline products and strategic acquisitions.
-
Potential for Investment:
- Pfizer presents a potentially attractive investment opportunity due to its market leadership, strong cash flow, and conservative capital structure.
- Its lower valuation metrics compared to peers suggest potential upside if the market re-evaluates its growth prospects.
- However, investors should carefully consider the risks associated with patent expirations and competition from generic drugs.
-
Key Risks and Considerations:
- Patent expirations on key drugs could significantly impact Pfizer's revenue and profitability.
- Competition from generic drug manufacturers could erode market share and pricing power.
- Regulatory challenges and changes in healthcare policy could affect the pharmaceutical industry.
- The success of Pfizer's pipeline products is critical for future growth.
-
Overall Assessment:
- Pfizer is a market-leading pharmaceutical company with a strong financial position and attractive valuation.
- While its recent growth has been inconsistent, its strong cash flow and conservative capital structure provide a solid foundation for future success.
- Investors should carefully consider the risks and opportunities before making an investment decision.